Biography Jörg Renkawitz


Professional Experience

since 2018:  Endowed ‘Peter Hans Hofschneider Professor for Molecular Medicine (Foundation Experimental Biomedicine), W2, Biomedical Center (BMC), Ludwig Maximilians-University Munich, Germany

2014 - 2018:  Postdoctoral Researcher with  Prof. Dr. Michael Sixt, Institute of Science and Technology (IST), Vienna, Austria


Education

2008 - 2013: PhD (Dr.rer.nat) with Prof. Dr. Stefan Jentsch, Max-Planck Institute of Biochemistry, Martinsried,Germany

2006 - 2008: Master of Science in Biochemistry with minor subjects Cell Biology and Virology, Ludwig-Maximilians-University Munich, Germany

2008: Master Thesis Research with Dr. Michael Sixt, Max-Planck Institute of Biochemistry, Germany

2007: Research Internships at the US National Cancer Institute (Dr. M. Kashlev), Max-von-Pettenkofer Institute (Dr. Z. Ruzsics), and ETH Zurich (Prof. S. Werner)

2003 - 2006: Bachelor of Science in Biochemistry, Technical University Munich, Germany

2006: Bachelor Thesis Research with Dr. Henrik Daub, Max-Planck Institute of Biochemistry, Germany

2005: Research Internship, Prof. Dr. Patrick Cramer, Gene Center, Munich, Germany

 

Honours, Fellowships & Major Grants

 

2024: Featured in ‘Cell Scientists to Watch’ series by the Journal of Cell Science

since 2021: Member of the DFG priority programme SPP2332 'Physics of Parasitism'

since 2020: Member of the 'EMBO Scientific Exchange Grants' Advisory Board

2019: Life Science Research Award Austria (category Basic Research)

since 2019: Member of the Collaborative Research Center SFB914 'Leukocyte trafficking', PI project A12

since 2018: Endowed ‘Peter Hans Hofschneider Professor for Molecular Medicine’

2015 - 2017: EMBO postdoctoral fellowship

2014 - 2015: ISTFELLOW postdoctoral fellowship, Marie-Curie COFUND

2013: Max-Planck-Institute of Biochemistry Junior Research Award

2013: PhD ‘summa cum laude’

2009 - 2012: PhD fellowship of the Boehringer-Ingelheim-Fonds (BIF)

2008 - 2013: International Max Planck Research School (IMPRS)